Q2 2025 Belite Bio Inc Earnings Call Transcript
Key Points
- Belite Bio Inc (BLTE) has made significant progress in advancing Tinlarebant for Stargardt disease and Geographic Atrophy, with Phase 3 trials underway.
- Tinlarebant has received multiple designations, including Breakthrough Therapy, Rare Pediatric Disease, and Fast Track in the US, as well as Orphan Drug Designation in the US, Europe, and Japan.
- The company successfully completed enrollment for its global Phase 3 study in Geographic Atrophy with 529 subjects.
- Belite Bio Inc (BLTE) raised $15 million in gross proceeds through a registered direct offering, strengthening its financial position.
- The company has a strong balance sheet with a cash runway expected to last for four years, allowing it to complete all three Phase 3 trials without additional funding.
- Research and development expenses increased to $11 million in Q2 2025 from $9.1 million in the same period last year, driven by higher pass-through and manufacturing expenses.
- General and administrative expenses rose significantly to $6.5 million from $1.4 million in the previous year, primarily due to increased share-based compensation expenses.
- Belite Bio Inc (BLTE) reported a net loss of $16.3 million for Q2 2025, compared to a net loss of $9.5 million in the same period last year.
- The company faces uncertainty regarding the FDA's recommendation for a single study approval path, which requires robust statistical significance.
- Enrollment for the DRAGON II trial is slower than expected, although strategic timing was intended to avoid competition with DRAGON I.
Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio second-quarter 2025 earnings call. (Operator Instructions) I will now hand the call over to [Sophie Hunt] Please go ahead.
Good afternoon, everyone. Thank you for joining us. On the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Nathan Mata, Chief Scientific Officer; Dr. Hendrik Scholl, Chief Medical Officer; and Hao-Yuan Chuang; Chief Financial Officer.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now I'll turn the call over to Dr. Lin.
Thank you for joining today's call to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
